
Tucatinib Plus Trastuzumab Provides Durable Reponses in Patients With HER2-Positive mCRC
In the phase 2 MOUNTAINEER study, the investigational combination of tucatinib and trastuzumab achieved durable response in patients with metastatic colorectal cancer.

















